Anti-cancer drug T-DM1 benefits women with advanced breast cancer who have failed several previous treatments: results from TH3RESA trial
First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 28, 2013 Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news

Roche's Kadcyla helped people with advanced HER2-positive breast cancer live longer without their disease worsening in new phase III study
Roche today announced that Kadcyla (trastuzumab emtansine) significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival [PFS], a co-primary endpoint) compared to people who received a treatment of their physician's choice in an open-label phase III study called TH3RESA. (Source: Roche Media News)
Source: Roche Media News - September 28, 2013 Category: Pharmaceuticals Source Type: news

Anti-cancer drug T-DM1 benefits women with advanced breast cancer who've failed previous treatments
(ECCO-the European CanCer Organisation) First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib. The research will be presented in a late-breaking presentation to the European Cancer Congress in Amsterdam. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 27, 2013 Category: Cancer & Oncology Source Type: news

New patient-focused five minute Herceptin® (trastuzumab) jab given green light by regulators & NHS England
Patients with a very aggressive form of breast cancer known as HER2-positive, could now benefit from a new faster, more efficient delivery method of Herceptin. The subcutaneous (SC) injection, given just beneath the skin, can be completed in 2-5 minutes, compared to the traditional, relatively time-consuming 30-90 minute intravenous (IV) infusion.[v] This speedier form of delivery of Herceptin is now authorised for use in the UK after a licence was granted by the European Medicines Agency (EMA). In addition, NHS England has agreed to fund its use on the NHS... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 25, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

NHS England sanctions new breast cancer treatment injection
A new sub cutaneous (SC) form of the drug will be commissioned. Herceptin SC will primarily be used to treat women with early breast cancer who currently get the drug with chemotherapy before or after surgery. More .... (Source: NHS Networks)
Source: NHS Networks - September 25, 2013 Category: UK Health Authors: Maria Axford Source Type: news

New breast cancer jab could slash hours spent in hospital and help save the NHS millions
Sufferers are currently given regular infusions of the drug Herceptin via a drip – an ordeal lasting between 30 and 90 minutes – for just over a year in most cases. But the jab delivers the substance in only five minutes. (Source: the Mail online | Health)
Source: the Mail online | Health - September 24, 2013 Category: Consumer Health News Source Type: news

CHMP grants positive opinion for Roche's Kadcyla, the first antibody-drug conjugate for advanced HER2-positive breast cancer
Roche today announced that the European Union’s (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Kadcyla (trastuzumab emtansine or T-DM1) as a single agent, for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. (Source: Roche Media News)
Source: Roche Media News - September 20, 2013 Category: Pharmaceuticals Source Type: news

Therapeutic Human Monoclonal Antibodies Against Cancer
There are over 30 monoclonal antibodies that are FDA approved for a variety of diseases ranging from malignancies to autoimmune diseases to macular degeneration. These antibodies include murine, fully humanized, and chimeric antibodies. There are a number of monoclonal antibodies used in the treatment of malignancies; in fact, three of the top five grossing antibodies (bevacizumab, trastuzumab, and rituximab) are used in oncology Scolnik (mAbs 1:179–184, 2009). (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - September 20, 2013 Category: Allergy & Immunology Source Type: news

Potential personalised therapy for a specific kind of pancreatic cancer
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin. Pancreatic cancer is the fourth leading cause of cause of cancer death in Western societies, with a 5-year survival rate of less than 5%. It is a molecularly diverse disease, meaning that each tumour will respond only to specific treatments that target its unique molecular make-up... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 18, 2013 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news

Potential treatment for a specific kind of pancreatic cancer
(Garvan Institute of Medical Research) Researchers from Sydney's Garvan Institute of Medical Research have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2 percent of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2013 Category: Global & Universal Source Type: news

Short Course of Chemo Effective in Early-Stage HER2 Breast Cancer
Combining four cycles of docetaxel and cyclophosphamide with 1 year of trastuzumab may be a viable treatment option for women with HER2-amplified early-stage breast cancer regardless of their TOP2A status, according to the results of a phase II study. (Source: Cancer Network)
Source: Cancer Network - September 14, 2013 Category: Cancer & Oncology Source Type: news

Breast Cancer: Preop Targeted Tx Effective
SAN FRANCISCO (MedPage Today) -- Dual HER2-targeted neoadjuvant therapy led to odds of pathologic complete response similar to those associated with trastuzumab and chemotherapy, a meta-analysis suggested. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 10, 2013 Category: Hematology Source Type: news

Kadcyla (Ado-trastuzumab Emtansine Injection for IV Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 6, 2013 Category: Drugs & Pharmacology Source Type: news

Subcutaneous Trastuzumab (Herceptin) Approved in EUSubcutaneous Trastuzumab (Herceptin) Approved in EU
The subcutaneous administration of the targeted therapy is much quicker than the usual intravenous infusion, and opens up the possibility of patients using it at home. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 3, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

HER2-Positive Breast Cancer Patients Prefer Subcutaneous Trastuzumab
Results of the PrefHer study indicated that when given the option between subcutaneous trastuzumab and intravenous trastuzumab, significantly more patients with HER2-positive breast cancer preferred the subcutaneous administration. (Source: Cancer Network)
Source: Cancer Network - September 3, 2013 Category: Cancer & Oncology Source Type: news

New formulation of Roche's Herceptin wins EU approval
ZURICH (Reuters) - Swiss drugmaker Roche said on Monday the European Commission had approved a new formulation of its breast cancer drug Herceptin which allows the medicine to be administered more quickly. (Source: Reuters: Health)
Source: Reuters: Health - September 2, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer
Subcutaneous formulation is administered in two to five minutes, rather than 30 to 90 minutes with the standard intravenous form; Herceptin is used to treat more than 80,000 patients each year in Europe (Source: Roche Media News)
Source: Roche Media News - September 2, 2013 Category: Pharmaceuticals Source Type: news

Roche's new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission for the treatment of HER2-positive breast cancer, an aggressive sub-type of the disease. The approval is for both early and later stages of treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - September 2, 2013 Category: Pharmaceuticals Source Type: news

Roche’s injectable Herceptin formula endorsed by the EU
Roche has won EU approval for a new injectable formula of its breast cancer drug, Herceptin, to treat the HER2-positive type of the disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 2, 2013 Category: Pharmaceuticals Source Type: news

August's top stories: Novartis's MS drug investigation, Amgen buys Onyx
The US FDA is to investigate the brain infection of a patient receiving Novartis's MS drug and Amgen acquired US cancer drug producer Onyx Pharmaceuticals for $10.4bn, while EMA approves use of GSK's Tyverb with Herceptin. Pharmaceutical-technology.c… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 2, 2013 Category: Pharmaceuticals Source Type: news

Trastuzumab and Survival in Breast CancerTrastuzumab and Survival in Breast Cancer
What's the prognostic value of pathologic response in breast cancer patients receiving neoadjuvant chemotherapy and trastuzumab? Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

MSF Urges Countries Not to Trade Away Health as Trans-Pacific Trade Pact Negotiations Intensify
Bandar Seri Begawan, Brunei Darussalam/New York, August 22, 2013–The far-reaching Trans-Pacific Partnership Agreement (TPP) should be a force for improving health outcomes for the more than half a billion people in twelve countries affected by the pact, but instead negotiators are moving towards finalizing a deal that in fact would restrict access to affordable medicines and constrain governments’ ability to protect the health of their citizens, Doctors Without Borders/Médecins Sans Frontières (MSF) said today. Trade representatives from the U.S. and 11 Pacific Rim countries are in Brunei to neg...
Source: MSF News - August 23, 2013 Category: Global & Universal Source Type: news

GSK receives EMA approval for new Tyverb®
The European Medicines Agency (EMA) has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab). This combination is indicated for adult patients with breast cancer whose tumours over express HER2 (ErbB2) with hormone receptor-negative (HR-) metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy. You must sign in to continue reading this article Hide related content:  Show related content read more (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 22, 2013 Category: Drugs & Pharmacology Authors: mz_loader Tags: *** Editor's Pick Oncology Latest News Source Type: news

Individual cases to dictate MNC drug cos’ approach to patents
Roche’s decision to give up India patent for Herceptin unlikely to set a precedent, says MNC drug companies’ body. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 22, 2013 Category: Pharmaceuticals Source Type: news

GSK receives EMA approval for new Tyverb®
The European Medicines Agency (EMA) has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab). This combination is indicated for adult patients with breast cancer whose tumours over express HER2 (ErbB2) with hormone receptor-negative (HR-) metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 21, 2013 Category: Drugs & Pharmacology Source Type: news

EMA approves GSK’s Tyverb used in conjunction with Herceptin
The European Medicines Agency (EMA) has given marketing authorisation to GlaskoSmithKline for breast cancer drug Tyverb to be used in combination with Roche’s Herceptin in the European Union. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 20, 2013 Category: Pharmaceuticals Source Type: news

Roche drops India patent for breast-cancer drug
Swiss pharmaceutical giant Roche says it is abandoning a patent for top-selling breast cancer drug Herceptin in the Indian market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 17, 2013 Category: Pharmaceuticals Source Type: news

Roche Won't Pursue Indian Patent for Cancer Drug
Roche said it won't pursue a patent in India for its breast cancer drug Herceptin, which will allow local drug makers to offer a cheaper version to patients. (Source: WSJ.com: Health)
Source: WSJ.com: Health - August 17, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Roche Gives Up on India Patent for Breast Cancer DrugRoche Gives Up on India Patent for Breast Cancer Drug
Roche Holding AG has decided not to pursue a patent application for its breast cancer drug Herceptin (trastuzumab) in India, the Swiss company said. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 16, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche gives up on India patent for breast cancer drug
ZURICH (Reuters) - Roche Holding AG has decided not to pursue a patent application for its breast cancer drug Herceptin in India, the Swiss company said on Friday, as Western drugmakers come under pressure over high prices in the fast-growing market. (Source: Reuters: Health)
Source: Reuters: Health - August 16, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Roche drops Herceptin patent extension bid in India
Roche has decided not to pursue a patent extension until 2019 in India for its blockbuster cancer drug, Herceptin, clearing the way for generic drug makers to manufacture the drug. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 16, 2013 Category: Pharmaceuticals Source Type: news

Swiss drug major Roche to drop anti-cancer drug Herceptin patent in India
Roche's decision is a smart move, say IP experts, as there is no Indian company manufacturing this drug due to the complex science involved. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 15, 2013 Category: Pharmaceuticals Source Type: news

Roche Gives Up India Patent for Breast Cancer Drug
Roche Holding AG has decided not to pursue a patent application for its breast cancer drug Herceptin in India, the Swiss company said on Friday, as Western drugmakers come under pressure over high prices in the fast-growing market. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 15, 2013 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: news

GSK receives marketing authorisation from the European Commission for additional indication: Tyverb™ (lapatinib) in combination with trastuzumab for patients with HER2-positive, HR-negative metastatic breast cancer
GlaxoSmithKline announced today that the European Commission has granted an additional indication for Tyverb™ (lapatinib) to be used in combination with trastuzumab. (Source: GSK news)
Source: GSK news - August 14, 2013 Category: Pharmaceuticals Source Type: news

Trastuzumab Emtansine in HER-2-Positive Breast CancerTrastuzumab Emtansine in HER-2-Positive Breast Cancer
The introduction of trastuzumab in the treatment of HER-2-positive metastatic breast cancer patients favorably changed the natural history of this disease. So what's next? Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant Trastuzumab Plus Chemo in Primary Breast CancerNeoadjuvant Trastuzumab Plus Chemo in Primary Breast Cancer
Does the pathological complete response rate to trastuzumab in HER2-positive breast cancer depend on the level of HER2 mRNA expression? Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Faster injectable trastuzumab matches intravenous in response rates
Read the full story on MD Consult: Faster injectable trastuzumab matches intravenous in response rates (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - August 2, 2013 Category: Journals (General) Source Type: news

Huge increase in numbers surviving skin cancer
Eight out of 10 now survive the diseaseRelated items from OnMedicaScientists find key cause of drug resistance Breast cancer rate falls with decline in HRT useAlso in the pressHeat treatment improves survival from sarcomaBenefit of Herceptin in more breast cancer cases (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 22, 2013 Category: UK Health Source Type: news

PHARE: One-Year Trastuzumab Remains Standard for HER2-Positive Breast Cancer
A 6-month regimen of treatment with trastuzumab for HER2-positive breast cancer failed to show noninferiority with the standard 12-month treatment regimen after 3.5 years of follow-up in the open-label, randomized, phase III PHARE trial. (Source: Cancer Network)
Source: Cancer Network - July 3, 2013 Category: Cancer & Oncology Source Type: news

EU Says Yes to Subcutaneous Herceptin and Other ExtensionsEU Says Yes to Subcutaneous Herceptin and Other Extensions
A positive opinion in Europe has been issued for a subcutaneous formulation of trastuzumab, plus expanded indications for lapatinib and bortezomib. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology Obituary Source Type: news

Low-Dose Chemo for Low Toxicity in Breast CancerLow-Dose Chemo for Low Toxicity in Breast Cancer
Dr. Laura Orlando describes impressive early results in treating advanced HER2-positive breast cancer with a combination of trastuzumab and low-dose chemotherapy. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology Expert Interview Source Type: news

Roche's subcutaneous Herceptin gets EU green light
ZURICH (Reuters) - Swiss drugmaker Roche said on Friday that European regulators had given a green light to a new formulation of its breast cancer drug Herceptin, which it hopes will help extend the medicine's shelf life. (Source: Reuters: Health)
Source: Reuters: Health - June 28, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

CHMP recommends EU approval of Roche's Subcutaneous Herceptin for HER2 positive breast cancer
- New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients' time - Herceptin® is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year (Source: Roche Media News)
Source: Roche Media News - June 28, 2013 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche's Subcutaneous Herceptin for HER2 positive breast cancer
- New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients' time - Herceptin® is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (SIX: RO, ROG; OTCQX: RHHBY) is pleased to announce that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has today recommended EU approval of a subcutaneous formulation of Herceptin® (trastuzumab) for the treatment of patients with HER2-positive breast cancer. ...
Source: Roche Investor Update - June 28, 2013 Category: Pharmaceuticals Source Type: news

BOLERO-3: Adding Everolimus Improves PFS in HER2+ Breast Cancer
The addition of everolimus (Novartis) to combination trastuzumab/vinorelbine leads to a significant improvement in progression-free survival compared with placebo in advanced and metastatic HER2-positive breast cancer. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

Anti-Cancer Agent, Herceptin Obtained Approval for Dosage and Administration for Postoperative Adjuvant Chemotherapy in Breast Cancer in Japan
Please find attached a press release by Chugai (Source: Roche Investor Update)
Source: Roche Investor Update - June 14, 2013 Category: Pharmaceuticals Source Type: news

How Do We Know Which Cancer Therapies Really Work?
The FDA has approved more than 30 molecularly targeted agents in cancer in recent years, including prominent examples such as trastuzumab for breast cancer, sunitinib for renal cell cancer and bevacizumab for colorectal, non-small cell lung and renal cell cancers.06/13/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 13, 2013 Category: Cancer & Oncology Source Type: news

Herceptin - A Targeted Biologic Therapy for...
Read a description of Herceptin (trastuzumab), how it works, about the side effects, and get some self-care tips. Herceptin is given for HER2 positive breast cancer as a targeted biologic therapy. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 5, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

ASCO: Afinitor Quells Herceptin Resistance
CHICAGO (MedPage Today) -- A study presented here may help unravel the issue of resistance to trastuzumab (Herceptin), a drug that is central to the treatment of HER2-positive breast cancer. (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - June 4, 2013 Category: OBGYN Source Type: news

HERA Trial: Invasive Lobular Breast Carcinoma Patients Derived Same Benefit From Trastuzumab Maintenance
In the HERA trial, benefit for invasive lobular breast cancer patients with 1 year of trastuzumab maintenance was similar to invasive ductal carcinoma patients. (Source: Cancer Network)
Source: Cancer Network - May 7, 2013 Category: Cancer & Oncology Source Type: news